Microbial superantigens as virulence factors and ways to counteract their actions

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 9, 2003, Pages 642-646

  Tarkowski, Andrej ^a   Collins, L Vincent ^a   Jonsson, Ing Marie ^a   Eriksson, Kristina ^a   Sakiniene, Egidija ^a   Verdrengh, Margareta ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; VIRULENCE FACTOR;

ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN SPECIFICITY; AUTOIMMUNITY; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; DOWN REGULATION; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; REVIEW;

ANTI-BACTERIAL AGENTS; HUMANS; SHOCK, SEPTIC; STAPHYLOCOCCUS; STREPTOCOCCUS; SUPERANTIGENS; VIRULENCE;

EID: 0242351609     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310016330     Document Type: Review

References (26)

1. Andersen PS, Lavoie PM, Sekaly RP, Churchill H, Kranz DM, Schlievert PM, et al. Role of the T-cell receptor alpha chain in stabilizing TCR-superantigen-MHC class II complexes. Immunity 1999; 10: 473-83.
2. McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001; 55: 77-104.
3. Lindberg E, Nowrouzian F, Adlerberth I, Wold AE. Long-term persistence of superantigen-producing Staphylococcus aureus strains in the intestinal microflora of healthy infants. Pediatr Res 2000; 48: 741-7.
4. Llewelyn M, Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002; 2: 156-62.
5. Abdelnour A, Bremell T, Tarkowski A. Toxic shock syndrome toxin 1 contributes to the arthritogenicity of Staphylococcus aureus. J Infect Dis 1994; 170: 94-9.
6. Abdelnour A, Bremell T, Holmdahl R, Tarkowski A. Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci. Eur J Immunol 1994; 24: 1161-6.
7. Novick RP, Ross HF, Projan SJ, Kornblum J, Kreiswirth B, Moghazeh S. Synthesis of staphylococcal virulence factors is controlled by a regulatory RNA molecule. Embo J 1993; 12: 3967-75.
8. Balaban N, Collins LV, Cullor JS, Hume EB, Medina-Acosta E, Vieira da Motta O, et al. Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides 2000; 21: 1301-11.
9. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18: 1096-100.
10. Arad G, Levy R, Hillman D, Kaempfer R. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 2000; 6: 414-21.
11. Arad G, Hillman D, Levy R, Kaempfer R. Superantigen antagonist blocks Th1 cytokine gene induction and lethal shock. J Leukoc Biol 2001; 69: 921-7.
12. Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie JB. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 2001; 69: 875-84.
13. Bavari S, Dyas B, Ulrich RG. Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A. J Infect Dis 1996; 174: 338-45.
14. Nilsson IM, Verdrengh M, Ulrich RG, Bavari S, Tarkowski A. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect Dis 1999; 180: 1370-3.
15. Verdrengh M, Kum W, Chow A, Tarkowski A. The effect of site-specific monoclonal antibodies directed to toxic shock syndrome toxin-1 in experimental Staphylococcus aureus arthritis. Clin Exp Immunol 1999; 118: 268-70.
16. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9: 517-24.
17. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121-5.
18. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
19. Sakiniene E, Bremell T, Tarkowski A. Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Arthritis Rheum 1996; 39: 1596-605.
20. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama 2002; 288: 862-71.
21. Bean AG, Freiberg RA, Andrade S, Menon S, Zlotnik A. Interleukin 10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 1993; 61: 4937-9.
22. Hotchkiss RS, Swanson PE, Knudson CM, Chang KC, Cobb JP, Osborne DF, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999; 162: 4148-56.
23. Lehnert NM, Allen DL, Allen BL, Catasti P, Shiflett PR, Chen M, et al. Structure-based design of a bispecific receptor mimic that inhibits T-cell responses to a superantigen. Biochemistry 2001; 40: 4222-8.
24. Saha B, Jaklic B, Harlan DM, Gray GS, June CH, Abe R. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig. J Immunol 1996; 157: 3869-75.
25. Collins LV, Eriksson K, Ulrich RG, Tarkowski A. Mucosal tolerance to a bacterial superantigen indicates a novel pathway to prevent toxic shock. Infect Immun 2002; 70: 2282-7.
26. Li H, Llera A, Malchiodi EL, Mariuzza RA. The structural basis of T-cell activation by superantigens. Annu Rev Immunol 1999; 17: 435-66.